$GILD Company News
10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results 35 min ago - TheStreet.com
Regulus up big premarket on HCV therapeutic results 9:21 a.m. Today - Seeking Alpha
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results 8:39 a.m. Today - TheStreet.com
Priceline Is On Sale 6:54 a.m. Today - Seeking Alpha
Biogen Leads 5 Top Biotech Stocks As Earnings Loom 6:56 p.m. Oct. 21, 2014 - Investors Business Daily
Gilead Sciences: Pricing, Politics And Profits 3:23 p.m. Oct. 21, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – AMGN GILD REGN ACHN 2:00 p.m. Oct. 21, 2014 - InvestorPlace.com
BI begins enrollment in Phase 3 CRC trial 9:08 a.m. Oct. 21, 2014 - Seeking Alpha
Gilead Sciences: Clear The Dockets And Settle With Merck Already 9:07 a.m. Oct. 21, 2014 - Seeking Alpha
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
3 Drugs Stocks Pushing Industry Growth 1:17 p.m. Oct. 20, 2014 - TheStreet.com
Stocks Slide on Indiscriminate Selling 10:40 a.m. Oct. 20, 2014 - Barrons.com
LabCorp launches new HIV test 10:40 a.m. Oct. 20, 2014 - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Oct. 20, 2014 - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Oct. 20, 2014 - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results 35 min ago - TheStreet.com
Regulus up big premarket on HCV therapeutic results 9:21 a.m. Today - Seeking Alpha
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results 8:39 a.m. Today - TheStreet.com
Priceline Is On Sale 6:54 a.m. Today - Seeking Alpha
Biogen Leads 5 Top Biotech Stocks As Earnings Loom 6:56 p.m. Oct. 21, 2014 - Investors Business Daily
Gilead Sciences: Pricing, Politics And Profits 3:23 p.m. Oct. 21, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – AMGN GILD REGN ACHN 2:00 p.m. Oct. 21, 2014 - InvestorPlace.com
BI begins enrollment in Phase 3 CRC trial 9:08 a.m. Oct. 21, 2014 - Seeking Alpha
Gilead Sciences: Clear The Dockets And Settle With Merck Already 9:07 a.m. Oct. 21, 2014 - Seeking Alpha
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
3 Drugs Stocks Pushing Industry Growth 1:17 p.m. Oct. 20, 2014 - TheStreet.com
Stocks Slide on Indiscriminate Selling 10:40 a.m. Oct. 20, 2014 - Barrons.com
LabCorp launches new HIV test 10:40 a.m. Oct. 20, 2014 - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Oct. 20, 2014 - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Oct. 20, 2014 - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
